Intermediate Uveitis is an indication for drug development with over 9 pipeline drugs currently active. According to GlobalData, preregistered drugs for Intermediate Uveitis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Intermediate Uveitis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Intermediate Uveitis overview
Intermediate uveitis is a type of uveitis, which is an inflammation of the uvea, the middle layer of the eye. Intermediate uveitis specifically involves inflammation in the vitreous, a gel-like substance in the middle of the eye and lead to the formation of inflammatory cells and debris in the vitreous. Symptoms include floaters, blurred vision, eye pain and redness. Diagnosis includes comprehensive eye examination and ancillary tests, such as optical coherence tomography (OCT) and fluorescein angiography, used to assess the extent of inflammation and its impact on the retina.
For a complete picture of PTSR and LoA scores for drugs in Intermediate Uveitis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
